-
1
-
-
84924400067
-
-
Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Union L. Accessed January 07, 2014
-
Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official J. Eur. Union L 324. Available at http://eurlex.europa.eu/LexUr iServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF. Accessed January 07, 2014.
-
Official J. Eur.
, vol.324
-
-
-
2
-
-
84924400066
-
-
Annex 1: Manufacture of Sterile Medicinal Products. Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC
-
EudraLex. Volume 4: EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of Sterile Medicinal Products (2008). Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC. Available at http://ec.europa.eu/health/documents/eudralex/vol-4/index-en.htm
-
(2008)
EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use
, vol.4
-
-
-
3
-
-
84999999641
-
Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1)
-
European Commission. (2010). Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1). Official Journal of the European Union 2010/C 82/01. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C-.2010.082.01.0001.01.ENG
-
(2010)
Official Journal of the European Union 2010/C 82/01
-
-
-
4
-
-
84877820900
-
Mesenchymal stem/stromal cells: A new cells as drugs" paradigm. Efficacy and critical aspects in cell therapy
-
De Girolamo L, E Lucarelli, G Alessandri, MA Avanzini, ME Bernardo, E Biagi, AT Brini, D'Amico G, F Fagioli, et al. (2013). Mesenchymal stem/stromal cells: a new cells as drugs" paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des 19:2459-2473.
-
(2013)
Curr Pharm des
, vol.19
, pp. 2459-2473
-
-
De Girolamo, L.1
Lucarelli, E.2
Alessandri, G.3
Avanzini, M.A.4
Bernardo, M.E.5
Biagi, E.6
Brini, A.T.7
D'Amico, G.8
Fagioli, F.9
-
5
-
-
84876536833
-
Therapeutic potential of mesenchymal stem cells in regenerative medicine
-
Patel DM, J Shah and AS Srivastava. (2013). Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int 2013:496218.
-
(2013)
Stem Cells Int
, vol.2013
, pp. 496218
-
-
Patel, D.M.1
Shah, J.2
Srivastava, A.S.3
-
6
-
-
77952805220
-
Human mesenchymal stem cells and their use in cell-based therapies
-
Motaln H, C Schichor and TT Lah. (2010). Human mesenchymal stem cells and their use in cell-based therapies. Cancer 116:2519-2530.
-
(2010)
Cancer
, vol.116
, pp. 2519-2530
-
-
Motaln, H.1
Schichor, C.2
Lah, T.T.3
-
7
-
-
84862702680
-
Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications
-
Yi T and SU Song. (2012). Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 35:213-221.
-
(2012)
Arch Pharm Res
, vol.35
, pp. 213-221
-
-
Yi, T.1
Song, S.U.2
-
8
-
-
84893347301
-
Mesenchymal stem cells for regenerative therapy: Optimization of cell preparation protocols
-
Ikebe C and K Suzuki. (2014). Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int 2014:951512.
-
(2014)
Biomed Res Int
, vol.2014
, pp. 951512
-
-
Ikebe, C.1
Suzuki, K.2
-
9
-
-
84898466874
-
Mesenchymal stem cells: Immune evasive, not immune privileged
-
Ankrum JA, JF Ong and JM Karp. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 32:252-260.
-
(2014)
Nat Biotechnol
, vol.32
, pp. 252-260
-
-
Ankrum, J.A.1
Ong, J.F.2
Karp, J.M.3
-
10
-
-
2342482526
-
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
-
Le Blanc K, I Rasmusson, B Sundberg, C Götherström, M Hassan, M Uzunel and O Ringdén. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
-
(2004)
Lancet
, vol.363
, pp. 1439-1441
-
-
Le Blanc, K.1
Rasmusson, I.2
Sundberg, B.3
Götherström, C.4
Hassan, M.5
Uzunel, M.6
Ringdén, O.7
-
11
-
-
84858080480
-
Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
-
Von Bahr L, B Sundberg, L Lönnies, B Sander, H Karbach, H Hägglund, P Ljungman, B Gustafsson, H Karlsson, K Le Blanc and O Ringdén. (2012). Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 18:557-564.
-
(2012)
Biol Blood Marrow Transplant
, vol.18
, pp. 557-564
-
-
Von Bahr, L.1
Sundberg, B.2
Lönnies, L.3
Sander, B.4
Karbach, H.5
Hägglund, H.6
Ljungman, P.7
Gustafsson, B.8
Karlsson, H.9
Le Blanc, K.10
Ringdén, O.11
-
13
-
-
84922568930
-
Standardization of good manufacturing practicecompliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications
-
Wuchter P, K Bieback, H Schrezenmeier, M Bornhäuser, LP Müller, H Bönig, W Wagner, R Meisel, P Pavel, et al. (2015). Standardization of good manufacturing practicecompliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 17:128-139.
-
(2015)
Cytotherapy
, vol.17
, pp. 128-139
-
-
Wuchter, P.1
Bieback, K.2
Schrezenmeier, H.3
Bornhäuser, M.4
Müller, L.P.5
Bönig, H.6
Wagner, W.7
Meisel, R.8
Pavel, P.9
-
14
-
-
84924400064
-
-
Annex 2: Manufacture of Biological active substances and Medicinal Products for Human Use. Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC
-
EudraLex. Volume 4: EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 2: Manufacture of Biological active substances and Medicinal Products for Human Use (2013). Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC. Available at http://ec.europa.eu/health/documents/eudralex/vol-4/index-en.htm
-
(2013)
EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use
, vol.4
-
-
-
15
-
-
27944435821
-
Clarification of the nomenclature for MSC: The international society for cellular therapy position statement
-
Horwitz EM, K Le Blanc, M Dominici, I Mueller, I Slaper-Cortenbach, FC Marini, RJ Deans, DS Krause, A Keating; International Society for Cellular Therapy. (2005). Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7:393-395.
-
(2005)
Cytotherapy
, vol.7
, pp. 393-395
-
-
Horwitz, E.M.1
Le Blanc, K.2
Dominici, M.3
Mueller, I.4
Slaper-Cortenbach, I.5
Marini, F.C.6
Deans, R.J.7
Krause, D.S.8
Keating, A.9
-
16
-
-
40949143606
-
Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international workshop on placenta derived stem cells
-
Parolini O, F Alviano, GP Bagnara, G Bilic, HJ Bühring, M Evangelista, S Hennerbichler, B Liu, M Magatti, et al. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 26:300-311.
-
(2008)
Stem Cells
, vol.26
, pp. 300-311
-
-
Parolini, O.1
Alviano, F.2
Bagnara, G.P.3
Bilic, G.4
Bühring, H.J.5
Evangelista, M.6
Hennerbichler, S.7
Liu, B.8
Magatti, M.9
-
17
-
-
33846120651
-
Isolation of amniotic stem cell lines with potential for therapy
-
De Coppi P, G Bartsch Jr., MM Siddiqui, T Xu, CC Santos, L Perin, G Mostoslavsky, AC Serre, EY Snyder, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25:100-106.
-
(2007)
Nat Biotechnol
, vol.25
, pp. 100-106
-
-
De Coppi, P.1
Bartsch, G.2
Siddiqui, M.M.3
Xu, T.4
Santos, C.C.5
Perin, L.6
Mostoslavsky, G.7
Serre, A.C.8
Snyder, E.Y.9
-
18
-
-
84900517225
-
Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices
-
Sharma RR, K Pollock, A Hubel and D McKenna. (2014). Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54:1418-1437.
-
(2014)
Transfusion
, vol.54
, pp. 1418-1437
-
-
Sharma, R.R.1
Pollock, K.2
Hubel, A.3
McKenna, D.4
-
19
-
-
43049151898
-
Concise review: Wharton's jelly-derived cells are a primitive stromal cell population
-
Troyer DL and ML Weiss. (2008). Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 26: 591-599.
-
(2008)
Stem Cells
, vol.26
, pp. 591-599
-
-
Troyer, D.L.1
Weiss, M.L.2
-
20
-
-
84924354100
-
Human term placental cells: Phenotype, properties and new avenues in regenerative medicine
-
Caruso M, M Evangelista and O Parolini. (2012). Human term placental cells: phenotype, properties and new avenues in regenerative medicine. Int J Mol Cell Med 1:64-74.
-
(2012)
Int J Mol Cell Med
, vol.1
, pp. 64-74
-
-
Caruso, M.1
Evangelista, M.2
Parolini, O.3
-
21
-
-
33751168064
-
Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue
-
Izadpanah R, C Trygg, B Patel, C Kriedt, J Dufour, JM Gimble and BA Bunnell. (2006). Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 99:1285-1297.
-
(2006)
J Cell Biochem
, vol.99
, pp. 1285-1297
-
-
Izadpanah, R.1
Trygg, C.2
Patel, B.3
Kriedt, C.4
Dufour, J.5
Gimble, J.M.6
Bunnell, B.A.7
-
22
-
-
33745437684
-
Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue
-
Kern S, H Eichler, J Stoeve, H Klüter and K Bieback. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-1301.
-
(2006)
Stem Cells
, vol.24
, pp. 1294-1301
-
-
Kern, S.1
Eichler, H.2
Stoeve, J.3
Klüter, H.4
Bieback, K.5
-
23
-
-
80052642226
-
Human adipose-derived stromal cells efficiently support hematopoiesis in vitro and in vivo: A key step for therapeutic studies
-
De Toni F, S Poglio, AB Youcef, B Cousin, F Pflumio, P Bourin, L Casteilla and P Laharrague. (2011). Human adipose-derived stromal cells efficiently support hematopoiesis in vitro and in vivo: a key step for therapeutic studies. Stem Cells Dev 20:2127-2138.
-
(2011)
Stem Cells Dev
, vol.20
, pp. 2127-2138
-
-
De Toni, F.1
Poglio, S.2
Youcef, A.B.3
Cousin, B.4
Pflumio, F.5
Bourin, P.6
Casteilla, L.7
Laharrague, P.8
-
24
-
-
84866239471
-
Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells
-
Strioga M, S Viswanathan, A Darinskas, O Slaby and J Michalek. (2012). Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 21:2724-2752.
-
(2012)
Stem Cells Dev
, vol.21
, pp. 2724-2752
-
-
Strioga, M.1
Viswanathan, S.2
Darinskas, A.3
Slaby, O.4
Michalek, J.5
-
25
-
-
84890825183
-
Human adult stem cells from diverse origins: An overview from multiparametric immunophenotyping to clinical applications
-
Sousa BR, RC Parreira, EA Fonseca, MJ Amaya, FM Tonelli, SM Lacerda, P Lalwani, AK Santos, KN Gomes, et al. (2014). Human adult stem cells from diverse origins: an overview from multiparametric immunophenotyping to clinical applications. Cytometry A 85:43-77.
-
(2014)
Cytometry A
, vol.85
, pp. 43-77
-
-
Sousa, B.R.1
Parreira, R.C.2
Fonseca, E.A.3
Amaya, M.J.4
Tonelli, F.M.5
Lacerda, S.M.6
Lalwani, P.7
Santos, A.K.8
Gomes, K.N.9
-
26
-
-
84924408482
-
Implementing directive 2004/23/EC of the European parliament and of the council as regards certain technical requirements for the donation, procurement and testing AU8c of human tissues and cells
-
European Commission Directive 2006/17/EC of 8 February
-
European Commission Directive 2006/17/EC of 8 February 2006. Implementing Directive 2004/23/EC of the European Parliament and of the Council as Regards Certain Technical Requirements for the Donation, Procurement and Testing AU8c of Human Tissues and Cells. Official Journal of the European Union L 38/40. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2006:038:TOC
-
(2006)
Official Journal of the European Union L 38/40
-
-
-
27
-
-
0003975349
-
-
Commission Directive 2006/86/EC of 24 October. Implementing Directive 2004/23/ECof the European Parliament and of the Council As Regards Traceability Requirements, Notification of Serious Adverse Reactions and Events and Certain Technical Requirements for the Coding, Processing, Preservation, Storage and Distribution of HuAU8cman Tissues and Cells
-
Commission Directive 2006/86/EC of 24 October 2006. Implementing Directive 2004/23/ECof the European Parliament and of the Council As Regards Traceability Requirements, Notification of Serious Adverse Reactions and Events and Certain Technical Requirements for the Coding, Processing, Preservation, Storage and Distribution of HuAU8cman Tissues and Cells. Official Journal of the European Union L 294/32. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2006:294:TOC
-
(2006)
Official Journal of the European Union L 294/32
-
-
-
28
-
-
84923080928
-
-
EMA/CHMP/BWP/457920/2012 rev 1
-
European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use (CHMP) Guideline on the use of bovine serum in the manufacture of human biological medicinal products 2013. EMA/CHMP/BWP/457920/2012 rev 1. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000351.jsp&mid=WC0b01ac058002956c
-
(2013)
Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products
-
-
-
29
-
-
84924421268
-
Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products
-
EMA/410/01 rev.3
-
European Medicines Agency (EMA)/European Commission. (2011). Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products. EMA/410/01 rev.3. Official Journal of the European Union C 73/01. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-00351.jsp&mid=WC0b01ac058002956c
-
(2011)
Official Journal of the European Union C 73/01
-
-
-
30
-
-
84855264212
-
Multipotent mesenchymal stromal stem cell expansion by plating whole bone marrow at a low cellular density: A more advantageous method for clinical use
-
Mareschi K, D Rustichelli, R Calabrese, M Gunetti, F Sanavio, S Castiglia, A Risso, I Ferrero, C Tarella and F Fagioli. (2012). Multipotent mesenchymal stromal stem cell expansion by plating whole bone marrow at a low cellular density: a more advantageous method for clinical use. Stem Cells Int 2012:920581.
-
(2012)
Stem Cells Int
, vol.2012
, pp. 920581
-
-
Mareschi, K.1
Rustichelli, D.2
Calabrese, R.3
Gunetti, M.4
Sanavio, F.5
Castiglia, S.6
Risso, A.7
Ferrero, I.8
Tarella, C.9
Fagioli, F.10
-
31
-
-
77949890037
-
Clinical-grade production of human mesenchymal stromal cells: Occurrence of aneuploidy without transformation
-
Tarte K, J Gaillard, JJ Lataillade, L Fouillard, M Becker, H Mossafa, A Tchirkov, H Rouard, C Henry, et al. (2010). Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115:1549-1553.
-
(2010)
Blood
, vol.115
, pp. 1549-1553
-
-
Tarte, K.1
Gaillard, J.2
Lataillade, J.J.3
Fouillard, L.4
Becker, M.5
Mossafa, H.6
Tchirkov, A.7
Rouard, H.8
Henry, C.9
-
32
-
-
34547115673
-
Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells
-
Schallmoser K, C Bartmann, E Rohde, A Reinisch, K Kashofer, E Stadelmeyer, C Drexler, G Lanzer, W Linkesch and D Strunk. (2007). Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 47:1436-1446.
-
(2007)
Transfusion
, vol.47
, pp. 1436-1446
-
-
Schallmoser, K.1
Bartmann, C.2
Rohde, E.3
Reinisch, A.4
Kashofer, K.5
Stadelmeyer, E.6
Drexler, C.7
Lanzer, G.8
Linkesch, W.9
Strunk, D.10
-
33
-
-
84881102185
-
Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use
-
Trojahn Kølle SF, RS Oliveri, PV Glovinski, M Kirchhoff, AB Mathiasen, JJ Elberg, PS Andersen, KT Drzewiecki and A Fischer-Nielsen. (2013). Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use. Cytotherapy 15:1086-1097.
-
(2013)
Cytotherapy
, vol.15
, pp. 1086-1097
-
-
Trojahn Kølle, S.F.1
Oliveri, R.S.2
Glovinski, P.V.3
Kirchhoff, M.4
Mathiasen, A.B.5
Elberg, J.J.6
Andersen, P.S.7
Drzewiecki, K.T.8
Fischer-Nielsen, A.9
-
34
-
-
84899757858
-
Inactivated human platelet lysate with psoralen: A new perspective for mesenchymal stromal cell production in good manufacturing practice conditions
-
Castiglia S, K Mareschi, L Labanca, G Lucania, M Leone, F Sanavio, L Castello, D Rustichelli, E Signorino, et al. (2014). Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy 16:750-763.
-
(2014)
Cytotherapy
, vol.16
, pp. 750-763
-
-
Castiglia, S.1
Mareschi, K.2
Labanca, L.3
Lucania, G.4
Leone, M.5
Sanavio, F.6
Castello, L.7
Rustichelli, D.8
Signorino, E.9
-
35
-
-
68049116669
-
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs
-
Capelli C, A Salvade, O Pedrini, V Barbui, E Gotti, G Borleri, B Cabiati, D Belotti, P Perseghin, et al. (2009). The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy 11:403-413.
-
(2009)
Cytotherapy
, vol.11
, pp. 403-413
-
-
Capelli, C.1
Salvade, A.2
Pedrini, O.3
Barbui, V.4
Gotti, E.5
Borleri, G.6
Cabiati, B.7
Belotti, D.8
Perseghin, P.9
-
36
-
-
77955509074
-
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population
-
Lucchini G, M Introna, E Dander, A Rovelli, A Balduzzi, S Bonanomi, A Salvadè, C Capelli, D Belotti, et al. (2010). Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 16:1293-1301.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
, pp. 1293-1301
-
-
Lucchini, G.1
Introna, M.2
Dander, E.3
Rovelli, A.4
Balduzzi, A.5
Bonanomi, S.6
Salvadè, A.7
Capelli, C.8
Belotti, D.9
-
37
-
-
48249116583
-
-
Validation of analytical procedures: text and methodology Q2 (R1)
-
International Conference on Harmonization (ICH). Harmonised Tripartite Guideline. Validation of analytical procedures: text and methodology Q2 (R1). (2005). Available at http://www.ich.org/products/guidelines/quality/article/qualityguidelines.html
-
(2005)
Harmonised Tripartite Guideline
-
-
-
39
-
-
84883079475
-
Validation of analytical methods in compliance with good manufacturing practice: A practical approach
-
Rustichelli D, S Castiglia, M Gunetti, K Mareschi, E Signorino, M Muraro, L Castello, F Sanavio, M Leone, I Ferrero and F Fagioli (2013). Validation of analytical methods in compliance with good manufacturing practice: a practical approach. J Transl Med 11:197.
-
(2013)
J Transl Med
, vol.11
, pp. 197
-
-
Rustichelli, D.1
Castiglia, S.2
Gunetti, M.3
Mareschi, K.4
Signorino, E.5
Muraro, M.6
Castello, L.7
Sanavio, F.8
Leone, M.9
Ferrero, I.10
Fagioli, F.11
-
40
-
-
84900419750
-
Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use
-
Gálvez P, B Clares, M Bermejo, A Hmadcha and B Soria. (2014). Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. Stem Cells Dev 23:1074-1083.
-
(2014)
Stem Cells Dev
, vol.23
, pp. 1074-1083
-
-
Gálvez, P.1
Clares, B.2
Bermejo, M.3
Hmadcha, A.4
Soria, B.5
-
41
-
-
33747713246
-
Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement
-
Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
-
(2006)
Cytotherapy
, vol.8
, pp. 315-317
-
-
Dominici, M.1
Le Blanc, K.2
Mueller, I.3
Slaper-Cortenbach, I.4
Marini, F.5
Krause, D.6
Deans, R.7
Keating, A.8
Prockop, D.9
Horwitz, E.10
-
42
-
-
84877938781
-
Clinicalgrade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: Standardization of immune quality controls
-
Menard C, L Pacelli, G Bassi, J Dulong, F Bifari, I Bezier, J Zanoncello, M Ricciardi, M Latour, et al. (2013). Clinicalgrade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22:1789-1801.
-
(2013)
Stem Cells Dev
, vol.22
, pp. 1789-1801
-
-
Menard, C.1
Pacelli, L.2
Bassi, G.3
Dulong, J.4
Bifari, F.5
Bezier, I.6
Zanoncello, J.7
Ricciardi, M.8
Latour, M.9
-
43
-
-
84881092225
-
Immunological characterization of multipotent mesenchymal stromal cells-The international society for cellular therapy (ISCT) working proposal
-
Krampera M, J Galipeau, Y Shi, K Tarte, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). (2013). Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 159:1054-1061.
-
(2013)
Cytotherapy
, vol.159
, pp. 1054-1061
-
-
Krampera, M.1
Galipeau, J.2
Shi, Y.3
Tarte, K.4
Sensebe, L.5
-
44
-
-
0347627149
-
Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells
-
Stenderup K, J Justesen, C Clausen and M Kassem. (2003). Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33:919-926.
-
(2003)
Bone
, vol.33
, pp. 919-926
-
-
Stenderup, K.1
Justesen, J.2
Clausen, C.3
Kassem, M.4
-
45
-
-
0025371225
-
BacT/Alert: An automated colorimetric microbial detection system
-
Thorpe TC, ML Wilson, JE Turner, JL Di Guiseppi, M Willert, S Mirrett and LB Reller. (1990). BacT/Alert: an automated colorimetric microbial detection system. J Clin Microbiol 28:1608-1612.
-
(1990)
J Clin Microbiol
, vol.28
, pp. 1608-1612
-
-
Thorpe, T.C.1
Wilson, M.L.2
Turner, J.E.3
Di Guiseppi, J.L.4
Willert, M.5
Mirrett, S.6
Reller, L.B.7
-
46
-
-
35148856663
-
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms
-
Bernardo ME, N Zaffaroni, F Novara, AM Cometa, MA Avanzini, A Moretta, D Montagna, R Maccario, R Villa, et al. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67:9142-9149.
-
(2007)
Cancer Res
, vol.67
, pp. 9142-9149
-
-
Bernardo, M.E.1
Zaffaroni, N.2
Novara, F.3
Cometa, A.M.4
Avanzini, M.A.5
Moretta, A.6
Montagna, D.7
MacCario, R.8
Villa, R.9
-
47
-
-
34247510646
-
Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro
-
Zhang ZX, LX Guan, K Zhang, S Wang, PC Cao, YH Wang, Z Wang and LJ Dai. (2007). Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int 31:645-648.
-
(2007)
Cell Biol Int
, vol.31
, pp. 645-648
-
-
Zhang, Z.X.1
Guan, L.X.2
Zhang, K.3
Wang, S.4
Cao, P.C.5
Wang, Y.H.6
Wang, Z.7
Dai, L.J.8
-
48
-
-
79961138790
-
Largescale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells
-
Ben-David U, Y Mayshar and N Benvenisty. (2011). Largescale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 9:97-102.
-
(2011)
Cell Stem Cell
, vol.9
, pp. 97-102
-
-
Ben-David, U.1
Mayshar, Y.2
Benvenisty, N.3
-
49
-
-
84855510030
-
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells
-
Sensebé L, K Tarte, J Galipeau, M Krampera, I Martin, DG Phinney, Y Shi; MSC Committee of the International Society for Cellular Therapy. (2012). Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell 10:9-10.
-
(2012)
Cell Stem Cell
, vol.10
, pp. 9-10
-
-
Sensebé, L.1
Tarte, K.2
Galipeau, J.3
Krampera, M.4
Martin, I.5
Phinney, D.G.6
Shi, Y.7
-
50
-
-
84901705554
-
Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols
-
Capelli C, O Pedrini, G Cassina, O Spinelli, S Salmoiraghi, J Golay, A Rambaldi, U Giussani and M Introna. (2014). Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. Haematologica 99:e94-e97.
-
(2014)
Haematologica
, vol.99
, pp. e94-e97
-
-
Capelli, C.1
Pedrini, O.2
Cassina, G.3
Spinelli, O.4
Salmoiraghi, S.5
Golay, J.6
Rambaldi, A.7
Giussani, U.8
Introna, M.9
-
51
-
-
84878611378
-
Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints
-
Barkholt L, E Flory, V Jekerle, S Lucas-Samuel, P Ahnert, L Bisset, D Büscher, W Fibbe, A Foussat, et al. (2013). Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints. Cytotherapy 15:753-759.
-
(2013)
Cytotherapy
, vol.15
, pp. 753-759
-
-
Barkholt, L.1
Flory, E.2
Jekerle, V.3
Lucas-Samuel, S.4
Ahnert, P.5
Bisset, L.6
Büscher, D.7
Fibbe, W.8
Foussat, A.9
-
52
-
-
84886630589
-
Human adipose stromal cells (ASC) for the regeneration of injured cartilage display genetic stability after in vitro culture expansion
-
Neri S, P Bourin, J-A Peyrafitte, L Cattini, A Facchini and E Mariani. (2013). Human adipose stromal cells (ASC) for the regeneration of injured cartilage display genetic stability after in vitro culture expansion. PLoS One 8:e77895.
-
(2013)
PLoS One
, vol.8
, pp. e77895
-
-
Neri, S.1
Bourin, P.2
Peyrafitte, J.-A.3
Cattini, L.4
Facchini, A.5
Mariani, E.6
-
53
-
-
84884922980
-
Genomic alterations in human umbilical cord-derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach
-
Borghesi A, MA Avanzini, F Novara, M Mantelli, E Lenta, V Achille, RM Cerbo, C Tzialla, S Longo, et al. (2013). Genomic alterations in human umbilical cord-derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach. Cytotherapy 15:1362-1373.
-
(2013)
Cytotherapy
, vol.15
, pp. 1362-1373
-
-
Borghesi, A.1
Avanzini, M.A.2
Novara, F.3
Mantelli, M.4
Lenta, E.5
Achille, V.6
Cerbo, R.M.7
Tzialla, C.8
Longo, S.9
-
54
-
-
34247589774
-
Cytogenetic guidelines and quality assurance: A common European framework for quality assessment for constitutional and acquired cytogenetic investigations
-
Hastings RJ, S Cavani, FD Bricarelli, PC Patsalis, U Kristoffersson; ECA PWG Co-ordinators. (2007). Cytogenetic Guidelines and Quality Assurance: a common European framework for quality assessment for constitutional and acquired cytogenetic investigations. Eur J Hum Genet 15:525-527.
-
(2007)
Eur J Hum Genet
, vol.15
, pp. 525-527
-
-
Hastings, R.J.1
Cavani, S.2
Bricarelli, F.D.3
Patsalis, P.C.4
Kristoffersson, U.5
|